COMMUNIQUÉS West-GlobeNewswire

-
Stemline Therapeutics Announces Validation of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA)
30/01/2019 -
Aino Health AB (publ): Aino Health signs partnership agreement with Uudenmaan Työterveys, (Nylands Arbetshälsa)
30/01/2019 -
Kamada Appoints Senior Biopharmaceutical Executive Michal Ayalon, Ph.D., as Vice President of Research and Development
30/01/2019 -
Mithra Announces Positive Top-line Results of Estelle® Phase III Oral Contraceptive Study in U.S/Canada
30/01/2019 -
Emerald Health Therapeutics Announces Discharge of Litigation
30/01/2019 -
Eyenovia Announces Positive Results in the MicroStat MIST-1 Phase III Registration Study for Mydriasis
30/01/2019 -
Trevena Announces $10 Million Registered Direct Offering of Common Stock
30/01/2019 -
Axsome Therapeutics Initiates Phase 2 Trial of AXS-12 in Narcolepsy
30/01/2019 -
Terveystalo Plc: Proposals of the Shareholders Nomination Board to the Annual General Meeting 2019
30/01/2019 -
Release date of annual report 2018 for ALK and audio cast
30/01/2019 -
Enzymatica AB: First patients included in large placebo-controlled multicentre study on ColdZyme
30/01/2019 -
Changes to the Nomination Committee for Immunicum AB (publ)
30/01/2019 -
Curetis’ Unyvero Application Cartridges Receive Regulatory Approvals in Malaysia and Thailand
30/01/2019 -
Orphazyme reports positive results from full data set of Phase II/III arimoclomol trial in Niemann-Pick disease Type C (NPC)
30/01/2019 -
Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018
30/01/2019 -
En 2018, Novartis a enregistré une forte croissance de ses ventes, avec une expansion de sa marge core, développé des plates-formes leaders de traitements de pointe, et recentré l'entreprise
30/01/2019 -
Bone Therapeutics SA: Information on the total number of voting rights and shares
30/01/2019 -
Bone Therapeutics SA : Information relative au nombre total de droits de vote et d’actions
30/01/2019 -
ASLAN Pharmaceuticals Announces Strategic Prioritisation of Clinical Development Programs and Corporate Restructuring
29/01/2019
Pages